Fig. 3From: Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestationHBV DNA levels in different groups. There was no statistically significant difference between HBV DNA levels in telbivudine group and that in control group at baseline. HBV DNA levels at 2 weeks, 4 weeks and 8 weeks in telbivudine group was lower than that at the same time in control group (P < 0.0001)Back to article page